ATE459642T1 - Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat - Google Patents

Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat

Info

Publication number
ATE459642T1
ATE459642T1 AT05763889T AT05763889T ATE459642T1 AT E459642 T1 ATE459642 T1 AT E459642T1 AT 05763889 T AT05763889 T AT 05763889T AT 05763889 T AT05763889 T AT 05763889T AT E459642 T1 ATE459642 T1 AT E459642T1
Authority
AT
Austria
Prior art keywords
chlorotoxin
myeloid
diagnosis
derivative
treatment
Prior art date
Application number
AT05763889T
Other languages
English (en)
Inventor
Vernon Alvarez
Matthew Gonda
Original Assignee
Transmolecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmolecular Inc filed Critical Transmolecular Inc
Application granted granted Critical
Publication of ATE459642T1 publication Critical patent/ATE459642T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05763889T 2004-04-06 2005-04-06 Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat ATE459642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55943304P 2004-04-06 2004-04-06
PCT/US2005/011523 WO2005099774A2 (en) 2004-04-06 2005-04-06 Diagnosis and treatment of myeloid and lymphoid cell cancers

Publications (1)

Publication Number Publication Date
ATE459642T1 true ATE459642T1 (de) 2010-03-15

Family

ID=35150508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763889T ATE459642T1 (de) 2004-04-06 2005-04-06 Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat

Country Status (9)

Country Link
US (1) US20110311445A1 (de)
EP (1) EP1756270B1 (de)
JP (2) JP2007532879A (de)
AT (1) ATE459642T1 (de)
AU (1) AU2005232616A1 (de)
CA (1) CA2561494A1 (de)
DE (1) DE602005019728D1 (de)
ES (1) ES2339683T3 (de)
WO (1) WO2005099774A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006020710D1 (de) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
HRP20171291T1 (hr) 2010-02-04 2017-10-20 Morphotek, Inc. Polipeptidi i konjugati klorotoksina i njihove uporabe
CN103097403B (zh) 2010-05-11 2017-04-19 弗雷德哈钦森癌症研究中心 氯毒素变体、缀合物及其使用方法
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
RU2473901C1 (ru) * 2012-02-22 2013-01-27 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ быстрой диагностики перевиваемого пролимфоцитарного лейкоза у мышей линии akr/jy
CA2913127A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2016001276A1 (en) * 2014-07-02 2016-01-07 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas
CA3001833A1 (en) * 2015-10-13 2017-04-20 City Of Hope Chimeric antigen receptors containing a chlorotoxin domain
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
JP7080478B2 (ja) * 2017-09-14 2022-06-06 株式会社西部技研 ガス置換用ドライルーム
CN111542345B (zh) 2017-09-15 2025-02-25 卫材公司 氯毒素剂及其用途
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345959A1 (en) * 2001-06-26 2003-01-08 Uab Research Foundation Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
JP2005537234A (ja) * 2002-05-31 2005-12-08 トランスモルキュラー インコーポレイテッド クロロトキシンとの併用化学療法
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
ES2339683T3 (es) 2010-05-24
EP1756270B1 (de) 2010-03-03
JP2011149961A (ja) 2011-08-04
US20110311445A1 (en) 2011-12-22
EP1756270A4 (de) 2007-10-24
WO2005099774A3 (en) 2006-03-23
WO2005099774A2 (en) 2005-10-27
DE602005019728D1 (de) 2010-04-15
EP1756270A2 (de) 2007-02-28
AU2005232616A1 (en) 2005-10-27
JP2007532879A (ja) 2007-11-15
CA2561494A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
DE602005019728D1 (de) Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
BRPI0507984A (pt) composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto
EA200601107A1 (ru) Композиции, получаемые из морских растений, для обеспечения питания для старческой и поврежденной окружающей средой кожи
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
DE602004013792D1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
EA201791669A2 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
EA201000105A1 (ru) Химические соединения
CY1113723T1 (el) Μεθοδος για θεραπεια συνδρομου ευερεθιστου εντερου επικρατουσας δυσκοιλιοτητας
GEAP201811194A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
NO20073665L (no) 2-fenoksy-N-(1,3,4-tiadizol-2-yl) Pyridin-3-aminderivater og beslektede forbindelser som P2Y1 reseptor inhibitorer for behandling av tromboemboliforstyrrelser
EA200800047A1 (ru) Производные пиримидина
DE602004017481D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
NO20072290L (no) Organiske forbindelser.
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
ATE406353T1 (de) Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten
MY146920A (en) Aminothiazole derivatives and their uses as antibacterial agents
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
NO20064659L (no) Nye kvarterniserte quinuklidin-estere
DE10390950D2 (de) Vorrichtung zur Behandlung von Patienten mittels Hirnstimulation
BRPI0518000A (pt) tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina
EA201001427A1 (ru) Тиазолилдигидроиндазолы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties